A study on genetic polymorphism in Matrix Metalloproteinases-3 in oral submucous fibrosis patients and in healthy individuals
© The Author(s) 2016
Received: 10 June 2016
Accepted: 14 October 2016
Published: 28 February 2017
OSF is a potentially malignant condition affecting the oral cavity and oropharynx. MMP-3 also known as Stromelysin -I is a key member of the MMP family which is responsible for degradation of collagen type II,IV,V,IX and X, proteoglycans, gelatins, fibronectin, laminin and elastin. It plays an important role in activation of pro MMP-1 into the active form of MMP-1 in malignant tissues. MMP-3 expression is low in normal tissues but it is altered during tumour formation, where remodeling of ECM is required.
Purpose of the study
To assess the association of single-nucleotide polymorphisms, Adenosine (Insertion/Deletion) in -1171 5A > 6A in the MMP-3 promoter regions of patients with oral submucous fibrosis and in healthy individuals (controls).
Thirty cases of OSF were categorized according to Khanna et al classification into four groups and Twenty age and sex matched controls were included in the study. Blood samples were collected in EDTA coated vacutainers and PCR restriction analysis was done. A statistical analysis was done using Chi-square test and Fisher’s exact test to assess the frequency and association of the alleles in the case-control group.
The result showed a statistical significance difference between the duration of habit and disease severity with polymorphisms. The result also showed a higher frequency of the 5A allele in the study group as compared to the controls.
A long-term follow up of these patients is mandatory to see the prognosis and their susceptibility to malignancy. The positive outcome of an association of the disease with polymorphisms would result in the development of potential diagnostic and therapeutic possibilities in potentially malignant and malignant lesions.
KeywordsMMP-3 Oral submucous fibrosis Genetic polymorphism
Potentially malignant disorders of the oral mucosa are pathologies that have an increased potential for malignant transformation at any site in the mouth and oropharynx . Worldwide, estimates of Oral submucous fibrosis (OSF) shows a confinement to Indians and Southeast Asians, with overall prevalence rate in India to be about 0.2 to 0.5% and prevalence by gender varying from 0.2 to 2.3% in males and 1.2–4.57% in females. It is predominantly seen in the second or third decade, and recent data suggest a male predominance; however, both sexes are equally at risk .
The condition is thought to be multifactorial in origin with a high incidence in people who chew arecanut, and a significant malignant transformation rate (7–30%)poses global problems for public health. In an epidemiological study on oral cancer and potentially malignant lesions in a rural Indian population, the malignant transformation rate of OSF was 7.6% over a 17-year period observation .
OSF is histopathologically characterized by fibrosis of subepithelial connective tissue. Collagens are the major structural component of extracellular matrix (ECM), hence precise regulation of collagen metabolism is essential to maintain the normal integrity of connective tissue. OSF is not only due to excessive deposition but also due to decreased collagen degradation. In OSF the equilibrium between Matrix Metalloproteinases (MMPs) and Tissue inhibitor matrix metalloproteinases (TIMP) is disturbed in such a manner that it ultimately results in increased deposition of ECM. Since OSF is considered as a high-risk pre-cancerous condition, knowledge of genetic susceptibility to malignant transformation is of immense importance, especially in developing cancer predictive markers for OSF patients.
Matrix metalloproteinases (MMPs) are a group of structurally related zinc-dependent endopeptidases and have the capability to degrade all components of extracellular Matrix. To date, at least 25 different vertebrate MMPs have been identified, 24 of which are present in humans, including two recently duplicated genes encoding MMP-23 . These MMPs are classified into five main classes (collagenases, gelatinases, stromelysins, membrane-type and others, including the matrilysin) on the basis of their putative substrate specificity and internal homologies.
The evidence that individual characteristics play an important role in physiological and pathological processes has resulted in the targeted study of genetic polymorphisms in the clinical setting. In this context, mediators that degrade ECM, such as matrix metalloproteinases (MMPs), are highlighted in studies involving inflammatory and degenerative diseases, and principally the prognosis and metastasis of cancer . For MMP genes, functional nucleotide polymorphism regulate the movement and metastasis of cancer cells .
MMP-3 also known as stromelysins I is a key member of this MMP family which is responsible for degradation of collagen type II,IV,V,IX and X, proteoglycans, gelatins, fibronectin, laminin and elastin. It plays an important role in activation of pro MMP-1 into the active form of MMP-1 in malignant tissues. MMP-3 expression is low in normal tissues but it is altered during tumour formation, where remodeling of ECM is required .
Common bi-allelic single nucleotide polymorphisms are found in promoter region of several MMPs. The promoter regions control transcription of the gene function. The promoter region of MMP3 is characterized by a 5A/6A promoter polymorphism at position -1171 in which one allele has six adenosine (6A) and the second has five adenosine (5A). A single adenosine insertion/deletion polymorphism (5A/6A) at position -1171 of the MMP-3 promoter region causes different transcription of MMP-3 expression. Such genetic polymorphisms are vital because they can be used as biomarkers that indicate for prognosis of potentially malignant and malignant lesions and thus may be involved in early intervention and diagnosis in patients at high risk .
The presence of the 5A allele has been associated with susceptibility for coronary heart disease, abdominal aneurysm and inflammatory disorders such as areca-related oral submucous fibrosis, celiac disease as well as ovarian and breast carcinomas [8–11]. By contrast, the 6A allele has been associated with carotid intima-media thickening and the progression of coronary artery disease, restenosis after balloon angioplasty, angiographic coronary atherosclerotic lesion growth and stenosis suggesting that a lower expression may result in matrix accumulation, faster arterial wall thickening and plaque progression [6, 12].
Thus, we conducted a cross- sectional case control study with the purpose of evaluating the association of promoter(-1171 5A- > 6A) polymorphism in the MMP-3 gene in patients suffering from Oral submucous fibrosis. The main aim and objective of this study was to correlate the association of -1171 5A > 6A polymorphism in the MMP-3 gene in OSF patients and healthy individuals (controls) and to to assess the association of single-nucleotide polymorphisms, Adenosine (Insertion/Deletion) polymorphism in -1171 5A > 6A in the MMP-3 promoter regions of patients with oral submucous fibrosis.
The study was conducted to assess the genetic polymorphism of MMP-3 gene in oral submucous fibrosis(OSF). This study included patients with OSF and healthy individuals as controls. They were selected at random from among the patients visiting the Department of Oral Medicine and Radiology, SDM College of Dental Sciences, Sattur, Dharwad, India. Prior to the collection of clinical samples ethical clearance was obtained from the institution review board (IRB No.2013/P/OM/16). This case-control study group included 50 participants of which 30 patients suffered from OSF and 20 controls were apparently healthy individuals devoid of any habits related to tobacco chewing or smoking or alcohol consumption. The study was conducted during the period of June 2014 to September 2015.
Inclusion criteria for the study group comprised of clinically and histopathologically proven OSF and for controls age and sex matched apparently consenting healthy cases.
Exclusion criteria included cases with prior history of cancer, pregnant women, previously treated or under the course of treatment of OSMF, hematological and autoimmune disorders.
Along with the samples patient’s information pertaining to socio-demographic factor such as age, sex, religion, habits, education, occupation, income, marital status, diet, family history were collected as per predesigned data collection sheet. A consent form in vernacular was prepared to obtain the informed consent from the subjects.
Peripheral Blood Mononuclear Cell (PBMC) samples were collected from consenting subjects after obtaining their informed consent. EDTA coated vacutainers were used for the collection of 3–4 ml PBMC. The collection tubes were coded and transported to the laboratory in ice-cold condition (4 °C).
DNA was isolated using standard isolation kit (DNeasy Blood and Tissue Kit, Cat. No. 69506, QIAGEN, USA). After optimization, genomic DNA was isolated. The extracted DNA was quantified and purity was assayed using UV Spectrophotometer at 260 and 280 nm.
Genotyping of the MMP-3 promoter polymorphism
Polymerase chain reaction
The 25 μl PCR reaction mixture was prepared that had 0.2 μM forward and reverse primer each; 200 μM of dNTPs (NEB #NO447L); 1X Taq Buffer, 1unit Taq enzyme (NEB #MO273L); about 1000 ng of DNA made upto volume with nuclease free water.
The PCR was performed in three steps: first, 5 min at 94 °C; then, 35 cycles of 30 s at 94 °C, 30 s at 57 °C, and 90 s at 72 °C; lastly, 1 h at 72 °C. The amplicons were denatured for 5 min at 100 °C, and mixed with formamide-containing stop buffer, and then subjected to electrophoresis on 4% polyacrylamide gel.
Restriction enzyme digestion
The association of the variants of case-control group and the MMP-3 genotypes were analysed with Chi-Square test. Differences between the values were considered significant when P < 0.05.
The frequency of distribution and associations between the MMP-3 genotypes and the risk of disease genesis were estimated by odds ratio (OR), and 95%confidence interval (CI) were calculated by the Fisher’s exact test.
This research was taken up with the intention to study the association and correlation of single nucleotide polymorphism in OSF, healthy individuals and also to assess the association of this polymorphism, Adenosine (Insertion/Deletion) in -1171 5A > 6A in the MMP-3 promoter regions OSF patients. The results show the association of three genotypes 5A/5A, 5A/6A, 6A/6A and the variables.
The quantity of the products consumed showed a significant difference with the 5A/5A genotypes. The study group that showed the presence of the 5A/5A genotype, consumed less than 5 packets of tobacco per day.
On computing the chi-square test of association for duration, frequency, stages of OSF and genotypes, the association of duration of the habit and disease severity was significant with the genotypes.
On computing the fisher’s exact test we found a statistical significant association of the 5A allele and 6A allele with the study and control group. The frequency of the 5A allele in OSF cases was 84.6%and the frequency of the 6A allele was 56.32%. Thus, it was noted that the frequency of 5A genotype is higher in OSF when compared with controls.
Fibrosis is a dynamic change between fibrogenesis and fibrolysis with a net output toward fibrogenesis. OSF is a disease which can be induced by areca chewing producing disruption in stromal tissue and cytokine regulation. Similar to OSF, liver cirrhosis, radiation induced fibrosis, and systemic sclerosis also show imbalance in fibrotic hemostasis. Under different areca exposure history, polymorphisms of genes associated with collagen homeostasis were reported to be correlated with the risks of OSF .
India is the fourth largest consumer of tobacco/betel quid in the world and the third largest producer of tobacco/betel quid after China and Brazil. The synergistic effect on the carcinogenic potency of tobacco/betel quid in oral cancer by alcohol consumption is well-documented in the literature. There are about 250 million tobacco/betel quid users in India who account for about 19% of the betel quid users /betel quid users .
MMPs play an important role in fibrosis of the oral cavity. Various types of MMPs are known to be expressed and activated in patients with OSF and in HNSCC. OSF is a potentially malignant disorder, which can be induced by areca nut chewing. Due to excess chewing of areca nut; arecoline may increase the production of collagen fibers in the sub epidermal layer of buccal cavity and causes fibrosis. Chiu et al reported that areca chewing as well as polymorphism of genes associated with collagen homeostasis was correlated with risk of OSF . Shin et al suggested that polymorphism of transforming growth factor (TGF-a) related to an innate immune response was also found to associated with the risk of OSMF .
MMP-3 has a wide substrate specificity for various ECM components and the expression of MMP-3 is regulated at the transcription level where the promoter region of the gene corresponds to growth factors, cytokines and some environmental factors associated with ECM . Thus in our study the objective was to determine the association and correlation of single nucleotide polymorphism in OSF, healthy individuals and also to assess the association of this polymorphism, Adenosine (Insertion/Deletion) in -1171 5A > 6A in the MMP -3 promoter regions OSF patients.
Patients of OSF were diagnosed on the basis of clinical signs including trismus, presence of fibrotic bands in the oral cavity and were histopathologically confirmed. Emphasis was given to addictions like areca nut, tobacco and alcohol. MMP -3 promoter genotypes in patients with OSF and controls were analysed with respect to gender, age, habits like betel quid chewing with or without tobacco and alcohol intake.
Association of gender with 5A/5A,5A/6A,6A/6A in study and control groups
Chi square value
OSF has a malignant transformation rate of 7–30% and the pathogenesis is thought to be multifactorial. One of the main pathogenesis is the chewing of areca-nut. The carcinogenic effects of tobacco acting in synergy with areca-nut is well known, but the second report on betel quid by the International Agency for Research on Cancer (IARC) identified areca-nut as a “group one carcinogen .
In a study conducted by Seedat et.al it was interesting to note that some patients developed OSF after a short areca-exposing time. However the study concluded that chewing betel nut will lead to pathological changes in the mucosa, but, neither the frequency nor the duration of the habit, are accurate predictors of the extent of these changes or when they are likely to occur .
In a previously conducted study by Choudhary et.al with the MMP-3 gene polymorphism in OSF and HNSCC there was a significant difference in the MMP-3 genotype distribution between the areca nut with tobacco chewers and the non - chewers both in OSMF and HNSCC .
Distribution of the subjects based on the quantity of the products consumed
Less than 5 packs/day
More than 5 packs/day
Association of quantity of the habit with polymorphism
Quantity (No of packets per day)
Less than five
More than 5
Results of chi- square to evaluate association the variables in the study group to the genotypes
Chaudhary and colleagues in their study found that the 5A allele might play an important role in the susceptibility to HNC, as individuals with 5A/5A genotype had nearly two fold risk of HNSCC (OR = 1.94) when compared to controls . However, Tu and colleagues found that the 5A/5A genotype was associated with the risk of oral submucous fibrosis but not OSCC .
In a study conducted by Choudhary et al the frequency of 5A/6A or 5A/5A promoter genotypes having 5A alleles was associated with MMP-3 single nucleotide polymorphism (SNP) in OSF (5A allele frequency = 0.15, p = 0.01, OR = 2.26, 95% CI = 1.22–4.20). Similar difference was also found in MMP-3 genotype distribution in HNSCC (5A allele frequency = 0.13, p = 0.03, OR = 1.94, 95% CI 1.06–3.51) as compared to controls (5A allele frequency = 0.07) . Hence we evaluated the association of the genotypes in MMP-3 gene -1171 5A > 6A polymorphism in OSF patients and healthy individuals (controls) devoid of any habits. The entire population included in the study comprised of 50 individuals comprising of 30 cases and 20 controls. The total number of individuals exhibiting polymorphisms were 10.
In the OSF group the homozygous 5A > 5A genotypes were seen in 3 individuals and was not present in controls. The heterozygous 5A > 6A genotypes were seen in five individuals and in two controls. The 6A/6A genotype was distributed evenly in the study and control group. The presence of the 5A/6A genotype in the control group may suggest that these patients could be at a relative risk of developing OSF either due to the effects of environmental factors or the possibility of higher exposure of such individuals to the environmental factors since birth that must have resulted in the polymorphism.
Further, we also analysed the association of the frequency of 5A/6A or 5A/5A promoter genotypes having 5A alleles with MMP-3 single nucleotide polymorphism (SNP) in OSF and found that the frequency of the homozygous 5A allele and 6A allele present in the OSF group was more than controls. This result is similar to the study conducted by Choudhary et.al, which showed a significant difference in 5A allele frequency between OSF and HNSCC as compared with controls. The study concluded that the 5A genotype had a more than two fold risk for OSF (OR = 2.26) and little less in HNSCC (OR = 1.94) in relation to the control group .
This finding is also in accordance to the study conducted by Tu et al. on MMP3 functional promoter polymorphism in male areca users showing an association with the risk of OSF. The study also concluded that the genotypic linkage among the collagen-related genes, MMPs, TIMPs, and cytokines related to OSF formation requires more information to specify the risk of OSF in areca chewers .
Further study in the field is required with a larger sample size to highlight the role of the polymorphisms in the -1171 5A > 6A promoter of MMP3-gene with OSF and also their presence in healthy individuals. A long term follow up of these patients is mandatory to see the prognosis and their susceptibility to malignancy. Hence, the positive outcome of an association with polymorphisms would result in the development of potential diagnostic and therapeutic possibilities in potentially malignant and malignant lesions.
With respect to the categorization of study groups, tobacco /betel quid chewers with OSF were included; but to establish the role of polymorphism, inclusion of patients who had the tobacco habit but did not suffer from OSF could have been considered as well.
The possible errors during the chemical solvent preparation, the standardisation and method optimisation contribute to limitations in the analysis.
The logistics of transporting serum samples, maintaining a temperature of 4°c and carrying out the processing in a distant laboratory from the site of sample collection were possible limitations.
The reliability of the history of tobacco habit, with respect to the product, the duration and the frequency as elicited from the patient, is questionable.
The evidences supporting the relationship between OSF formation and MMPs expression are uncertain. Because the increased expression of TIMP-1 and its inhibitory activity toward MMP activity may underlie the pathogenesis of OSF, it is important to know whether the OSF subjects carrying 5A alleles in MMP3 had the genotypic repression of TIMP-1 .
Since OSF is considered as a high-risk pre-cancerous condition, knowledge of genetic susceptibility to malignant transformation is of immense importance, especially in developing cancer predictive markers for OSF patients .
Basic Fibroblastic growth factor
Connective tissue growth factor
Fibroblast growth factor
Head and Neck squamous cell carcinoma
Oral Premalignant lesions
- OSF /OSMF:
Oral submucous fibrosis
Plasminogen activation inhibitor
Single- nucleotide polymorphism
Transforming growth factor beta
Tissue inhibitor of metalloproteinases
Tumor necrosis factor
A sincere thanks to Dr. Venkatesh Naikmasur,Professor Department of Oral medicine and Radiology, for his support during the design of the study, to Mr. Bhushan B Kulkarni, Assistant Professor Department of Biotechnology PC Jabin College, for his guidance with the lab procedures and also with data acquisition and analysis. The authors are thankful to Dr. M.V Muddapur, biostatistician, for his guidance and interpretation of results with statistical methods to conclude this study. The authors are also grateful to Dr D Veerendra Heggade, President of SDME society and to Dr Srinath Thakur,Principal of SDM College of Dental Sciences, for providing all possible resources to conduct the study.
Availability of data and materials
The in-vitro study has been done in the biotechnology department of PC Jabin College Hubli.
The details of the materials used and the data collected have been included in the manuscript.
Data of the patients are collected in patients file in SDM College of Dental sciences.
PP carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. SH participated with the DNA isolation and PCR procedures. AP,KB and SH participated in the design of the study. MM performed the statistical analysis. PP, AS analysed the data of the study and participated in its design and coordination and helped to draft the manuscript. AP and KB approved the final version to be published. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
I have read and understood the consent form and the information provided to me. I was free to ask any questions and they have been answered. I exercise my free power of choice and hereby give my consent to be interviewed and examined by the investigators. I agree to cooperate for any investigations considered necessary for my treatment. I consent to the taking and publication of any photographs in the course of this procedure for the purpose of advancing health education. I understand that my identity will remain confidential.
The above consent form states the identity of the patient will remain confidential. Hence the images or the written data in the manuscript does not reveal the patients identity and does not breach his /her terms of privacy.
Ethics approval and consent to participate
IRB No.2013/P/OM/16. At the institutional review board meeting held on 15-11-2013,the study titled “A Study On Genetic Polymorphism In Matrix Metalloproteinases-3 In Oral Submucous Fibrosis Patients And In Controls.” Was presented and discussed. The Committee has decided to approve and grant ethical clearance for the study to be carried out by the Principal Investigator and Dr. Atul P Sattur as guide at SDM College of Dental Sciences and Hospital,Sattur,Dharwad.
All the members voted for the proposed study and none of the members voted against the proposed study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- de Freitas P, Simãμes A. Lasers in dentistry : Guide for clinical practice. 2015.View ArticleGoogle Scholar
- Arakeri G, Brennan PA. Oral submucous fibrosis: an overview of the aetiology, pathogenesis, classification, and principles of management. Br J Oral Maxillofac Surg. 2013;51:587–93.View ArticlePubMedGoogle Scholar
- Gupta MK, Mhaske S, Ragavendra R, Imtiyaz. Oral submucous fibrosis Current Concepts in Etiopathogenesis. People’s J Sci Res. 2008.
- Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet. 2003;4:544–58.View ArticlePubMedGoogle Scholar
- Chiu CT, Chuang CY, Chang SW, et al. Expression of Matrix Metalloproteinases in Oral Cancer Patients Who Are Betel Quid Users. Taiwan J Oral Maxillofac Surg. 2008;19:313–27.Google Scholar
- Munhoz FB, Godoy-Santos G, Santos MC. MMP-3 Polymorphism genetic marker in pathological processes. Mol Med Rep. 2010;3:735–40. 17:10.PubMedGoogle Scholar
- Chaudhary AK, Singh M, Bharti AC, Asotra K, Sundaram S, Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci. 2010;17:10.View ArticlePubMedPubMed CentralGoogle Scholar
- Mora B, Bonamico M, Ferri M, Megiorni F, Osborn J, Pizzuti A, Mazzilli MC. Association of the matrix metalloproteinase-3 (MMP-3) promoter polymorphism with celiac disease in male subjects. Hum Immunol. 2005;66:717–20.View ArticleGoogle Scholar
- Tu HF, Liu CJ, Chang CS, Lui MT, Kao SY, Chang CP, Liu TY. The functional –1171 (5A/6A) polymorphisms of matrix metalloproteinase 3 gene as a risk factor for oral submucous fibrosis among male areca users. Oral Pathol Med. 2006;35:99–103.View ArticleGoogle Scholar
- Yoon S, Tromb G, Vongpunsawad S, Ronkainen A, Juvonen T, Kuivaniemi H. Genetic analysis of MMP3 and MMP9 and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Communic. 1999;265:563–8.View ArticleGoogle Scholar
- Biondi ML, Turri O, Leviti S, Seminati R, Cecchini F, Bernini M, Ghilardi G, Guagnellini E. MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin Chem. 2000;46:2023–4.PubMedGoogle Scholar
- Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin- 1 promoter which results in reduced gene expression. J Biol Chem. 1996;271:13055–60.View ArticlePubMedGoogle Scholar
- Kadashetti V, et al. Analysis of various risk factors affecting potentially malignant disorders and oral cancer patients of Central India. J Cancer Res Ther. 2015;11(2).
- Shin YN, Liu CJ, Chang KW, Lee YJ, Liu HF. Association of CTLA-4 gene polymorphism with oral submucous fibrosis in Taiwan. J Oral Pathol Med. 2004;33:200–3.View ArticlePubMedGoogle Scholar
- Ahmad MS, Ali SA, Ali AS, Chaubey KK. Epidemiological and etiological study of oral sub mucous fibrosis among gutkha chewers of Patna, Bihar, India. J Indian Soc Pedod Prev Dent. 2006;24(2):84–9.View ArticlePubMedGoogle Scholar
- Reddy V, Wanjari P, Reddy N, Reddy P. Oral Submucous Fibrosis: Correlation of Clinical Grading to various habit factors. Int J Dent Clin. 2011;3(1):21–4.View ArticleGoogle Scholar
- Hazarey VK, Erewald DK, Mundhe KA, Ugadhe SN. Oral sub mucous fibrosis: study of 1000 cases form central India. J Oral Pathol Med. 2007;36(1):12–7.View ArticlePubMedGoogle Scholar
- Chang YC, Yang SF, Tai KW, Chou MY, Hsieh YS. Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol. 2002;38:195–200.View ArticlePubMedGoogle Scholar
- Rupak S, Baby GG, Padiyath S, Kumar KR. Oral sub mucous fibrosis and iron deficiency anaemia relationship revisited- results from an Indian study. E-J Dent. 2012;2(2):159–65.Google Scholar
- Katharia SK, Singh SP, Kulshreshtha VK. The effects of placental extract in management of oral sub mucous fibrosis. Indian J Pharmacol. 1992;24(3):181–3.Google Scholar
- Maher R, Aga P, Johnson NW, Sankaranarayanan R, Warnakulasuriya S. Evaluation of multiple micronutrient supplementations in the management of oral sub mucous fibrosis in Karachi, Pakistan. Nutr Cancer. 1997;27(1):41–7.View ArticlePubMedGoogle Scholar
- Gupta PC, Sinor PN, Bhonsle RB, Pawar VS, Mehta HC. Oral sub mucous fibrosis in India: A new epidemic? Natl Med J India. 1998;11(3):113–6.PubMedGoogle Scholar
- Ahmad MS, Ali SA, Ali AS, Chaubey KK. Comparative Severity of Oral Sub mucous Fibrosis among gutkha and other areca nut products chewers. Priory Med J.
- Shiau YY, Kwan HW. Sub mucous Fibrosis in Taiwan. Oral Surg. 1979;47(5):453–7.View ArticlePubMedGoogle Scholar
- Mukherjee D, Oommen AM, Ghom A, George K. Risk Factors Associated with Oral Sub Mucous Fibrosis (OSMF): A Case Control Study. IJHSR. 2014; 4 (7).
- Betel quid and areca-nut chewing and some areca nut derived nitrosamines. World Health Organization, IARC monographs on the evaluation of carcinogenic risks to Humans,Volume 85.
- Seedat HA, Van Wyk CW. The oral features of betel nut chewers without oral submucous fibrosis. J Biol Buccale. 1988;16(3):123–8.PubMedGoogle Scholar
- Chaudhary AK, Singh M, Bharti AC, Asotra K, et al. Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5a- > 6a) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer. 2010;10:369.View ArticlePubMedPubMed CentralGoogle Scholar
- Rajendran R, Karunakaran A. Further on the causation of oral submucous fibrosis. Indian J Dent Res. 2002;13:74–82.PubMedGoogle Scholar
- Rasika Priyadharshani Ekanayaka and Wanninayake Mudiyanselage Tilakaratne. Oral Submucous Fibrosis: Review on Mechanisms of Pathogenesis and Malignant Transformation J Carcinogene Mutagene,2013